Funding for this research was provided by:
IO Biotech ApS
Received: 29 May 2019
Accepted: 24 October 2019
First Online: 6 November 2019
Compliance with the ethical standards
: Mads Hald Andersen has filed several patent applications based on the use of arginase for vaccinations. The rights of the patent applications have been transferred to Copenhagen University Hospital, Herlev, in accordance with the Danish Law of Public Inventions at Public Research Institutions. The capital region has licensed these patents to the company IO Biotech ApS, whose purpose is to develop immune-modulating vaccines for cancer treatments. Mads Hald Andersen is a shareholder and board member of IO Biotech ApS. Evelina Martinenaite is employed by IO Biotech ApS. Other authors declare no conflict of interest.
: The protocol was approved by the Scientific Ethics Committee for the Capital Region of Denmark (H-A-2009-013) and conducted in accordance with the provisions of the Declaration of Helsinki.
: Written informed consent for the use of the PBMCs for research purposes was obtained from the patients and healthy donors prior to inclusion in the study.